QC
MRNA icon

Quent Capital’s Moderna MRNA Stock Holding History

Quent Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.1K Buy
516
+268
+108% +$13.9K ﹤0.01% 901
2026
Q1 		$12.6K Buy
248
+50
+25% +$2.33K ﹤0.01% 1107
2025
Q4 		$5.84K Sell
198
-108
-35% -$2.93K ﹤0.01% 1250
2025
Q3 		$7.9K Buy
+306
New +$8.54K ﹤0.01% 1066
2025
Q2 		– Sell
-294
Closed -$8.34K – 878
2025
Q1 		$8.34K Buy
294
+87
+42% +$3.09K ﹤0.01% 932
2024
Q4 		$8.61K Hold
207
– – ﹤0.01% 955
2024
Q3 		$13.8K Sell
207
-180
-47% -$16.5K ﹤0.01% 955
2024
Q2 		$46K Sell
387
-19
-5% -$2.4K 0.01% 654
2024
Q1 		$43.3K Sell
406
-34
-8% -$3.43K 0.01% 694
2023
Q4 		$43.8K Sell
440
-48
-10% -$4.04K 0.01% 648
2023
Q3 		$50.4K Buy
488
+23
+5% +$2.57K 0.01% 584
2023
Q2 		$56.5K Sell
465
-66
-12% -$8.8K 0.01% 560
2023
Q1 		$81.6K Buy
531
+22
+4% +$3.63K 0.01% 460
2022
Q4 		$91.4K Buy
509
+7
+1% +$1.15K 0.02% 420
2022
Q3 		$59K Buy
502
+85
+20% +$12.9K 0.01% 499
2022
Q2 		$60K Sell
417
-54
-11% -$7.72K 0.01% 471
2022
Q1 		$81K Sell
471
-291
-38% -$49K 0.02% 461
2021
Q4 		$194K Buy
+762
New +$223K 0.04% 294

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Quent Capital's MRNA Position: Q2 2026 in Review

Quent Capital increased its Moderna (MRNA) stake by 108% in Q2 2026, buying an estimated $13.9K and bringing the position to 516 shares worth $36.1K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

Quent Capital first reported a position in MRNA in Q4 2021 and has held it in 18 quarters since. The position peaked at $194K in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Quent Capital held 516 shares of Moderna worth $36.1K as of Q2 2026.
  • Quent Capital bought 268 Moderna shares in Q2 2026, an estimated $13.9K.
  • Moderna made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #901 holding.
  • Quent Capital first reported a position in Moderna in Q4 2021 and has held it in 18 quarters since.
  • Quent Capital's Moderna position peaked at $194K in Q4 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.